New perspectives on randomized controlled trials with omega-3 fatty acid supplements and cognition: A scoping review
Abstract
Long chain polyunsaturated omega-3 fatty acids (n-3 FA), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are known to be important components in a healthy diet and contribute to healthy functioning of the heart and the brain, among other organs. Although there are epidemiological studies on the strong relationship between fish or n-3 FA consumption and lower risk of cognitive decline, results from randomized controlled trials (RCTs) are less consistent. Here, we performed a scoping review on RCTs with n-3 FA supplementation where cognition was evaluated. Seventy-eight RCTs published before April 2022 were included in this review. Among these RCTs, 43.6% reported a positive cognitive outcome after the consumption of n-3 FA compared to the placebo. However, there was a large diversity of populations studied (age ranges and health status), wide range of doses of EPA + DHA supplemented (79 mg/day - 5200 mg/day) and a multitude of tests evaluating cognition, mainly diagnostic tests, that were used to assess cognitive scores and overall cognitive status. RCTs were thereafter categorized into non-cognitively impaired middle-aged adults (n = 24), non-cognitively impaired older adults (n = 24), adults with subjective memory complaints (n = 14), adults with mild cognitive impairments (MCI, n = 9) and people with diagnosed dementia or other cognitive changes (n = 7). Among these categories, 66.7% of RCTs conducted with MCI adults reported a positive cognitive outcome when supplemented with n-3 FA vs. the placebo. Therefore, this scoping review provides rationale and questions to a) strengthen the design of future RCTs with n-3 FA for cognitive outcomes, and b) generate more informative data to support clinicians in their practice in assessing cognition before and after a nutritional intervention.
Related
- Virtual Placebo: a scoping review of control conditions in randomized controlled trials of psychological immersive virtual reality interventions
- Delivering balanced energy and protein (BEP) supplements to pregnant and breastfeeding women in low- and middle-income countries: A scoping review
- A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials
- Porcine Adenovirus-Based Viral Vectors for Swine Vaccines: A Scoping Review and Future Perspectives.
- Effects of myofascial release on clinical outcomes and muscle viscoelastic properties in patients with breast cancer: A randomized controlled trial
BibTeX
@article{andriambelo2026perspectives,
title = {{New perspectives on randomized controlled trials with omega-3 fatty acid supplements and cognition: A scoping review}},
author = {B. Andriambelo and M. Stiffel and K. Roke and Melanie Plourde},
journal = {Ageing Research Reviews - ARR},
year = {2026},
month = oct,
doi = {10.1016/j.arr.2022.101835},
url = {https://hal.science/hal-05790356v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - New perspectives on randomized controlled trials with omega-3 fatty acid supplements and cognition: A scoping review
AU - B. Andriambelo
AU - M. Stiffel
AU - K. Roke
AU - Melanie Plourde
PY - 2026
DA - 2026/10/09
JO - Ageing Research Reviews - ARR
DO - 10.1016/j.arr.2022.101835
UR - https://hal.science/hal-05790356v1
AB - Long chain polyunsaturated omega-3 fatty acids (n-3 FA), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are known to be important components in a healthy diet and contribute to healthy functioning of the heart and the brain, among other organs. Although there are epidemiological studies on the strong relationship between fish or n-3 FA consumption and lower risk of cognitive decline, results from randomized controlled trials (RCTs) are less consistent. Here, we performed a scoping review on RCTs with n-3 FA supplementation where cognition was evaluated. Seventy-eight RCTs published before April 2022 were included in this review. Among these RCTs, 43.6% reported a positive cognitive outcome after the consumption of n-3 FA compared to the placebo. However, there was a large diversity of populations studied (age ranges and health status), wide range of doses of EPA + DHA supplemented (79 mg/day - 5200 mg/day) and a multitude of tests evaluating cognition, mainly diagnostic tests, that were used to assess cognitive scores and overall cognitive status. RCTs were thereafter categorized into non-cognitively impaired middle-aged adults (n = 24), non-cognitively impaired older adults (n = 24), adults with subjective memory complaints (n = 14), adults with mild cognitive impairments (MCI, n = 9) and people with diagnosed dementia or other cognitive changes (n = 7). Among these categories, 66.7% of RCTs conducted with MCI adults reported a positive cognitive outcome when supplemented with n-3 FA vs. the placebo. Therefore, this scoping review provides rationale and questions to a) strengthen the design of future RCTs with n-3 FA for cognitive outcomes, and b) generate more informative data to support clinicians in their practice in assessing cognition before and after a nutritional intervention.
SN - 1872-9649
ER -